Loading…
Pharmaceuticals · NSE · period ending 2026-03-31
Loading chart…
✓ Core business is permissible and non-compliant income is 0% of revenue (limit 5%).
| Ratio | Value | Limit | Result |
|---|---|---|---|
| Debt / 36-month avg market cap | 0% | < 33% | Pass |
| Cash + interest-bearing securities / 36-month avg market cap | 20.44% | < 33% | Pass |
| Accounts receivable / 36-month avg market cap | 0% | < 33% | Pass |
The underlying figures and the filing citations they came from are available with a free account.
Sign up free0% of any dividend from NATCOPHARM should be given to charity. Calculate your amount →
NATCOPHARM has seen a very sharp 1-month drop and double-digit 3-month decline, leaving it far below its 52-week high despite a still-positive longer-term moving-average structure. This combination reflects a strong corrective down phase within what had previously been a positive trend setup.
Computed from delayed price history and desk sentiment. Educational context only — not investment advice or a price prediction.
Compliance watch: verdict re-verified against live market cap on 13 Jun 2026 · rechecked every 6 hours · filings reviewed quarterly.